Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance

National Grid Transco PLC National Grid PLC (NEW) American Depositary SharesTrade
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)Trade

Price performance (Past 24H)

Key statistics

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.17 (market cap $78.25B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $19.4 (market cap $60.06B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is the larger of the two by market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays the higher dividend (4.14%). Which is the better fit depends on your goals.

NGGTAK
Market Cap
$78.25B$60.06B
Volume
1,070,0312,925,042
Sector
UtilitiesHealth
52-Week High
$93.93$19.05
52-Week Low
$73.54$13.23
Enterprise Value
$136.28B$87.89B
Dividend Yield
4.14%3.33%
Typical Hold Time
—6 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.

Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

TAK trades at $18.52, down 0.86% on the day. The stock shows mixed signals with a bullish technical outlook from moving averages but neutral oscillators. Recent financials reveal a net income margin of -3.54% for 2026, though revenue remains stable near $4.6 trillion. Positive developments include the launch of ORZEYFUL for narcolepsy and FDA priority review for zasocitinib, highlighting a robust pipeline. Cash flow improved to $209.8 billion in 2026 from a negative position in 2025.

Outlook: TAK's strong analyst support (83% buy ratings) and promising drug pipeline offer growth potential, but profitability concerns and high P/E of 51.56 pose risks. Investors should weigh pipeline successes against current negative margins and elevated valuation.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.

Read more on NGG →

About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.

Read more on TAK →